Stocktoria
Unicycive Therapeutics, Inc. UNCY
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-06-17
Unicycive Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $675,000 | $951,000 | — | — |
| R&D expense | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M |
| SG&A expense | — | — | — | $383,000 | $245,000 | $58,000 |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M | -$2.0M |
| Interest expense | — | — | $82,000 | $6,000 | $628,000 | $244,000 |
| Net income | -$26.6M | -$36.7M | -$30.5M | -$18.1M | -$10.0M | -$2.3M |
| EPS (diluted) | $-1.67 | $-5.65 | $-1.28 | $-1.20 | $-0.86 | — |
| Operating cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M | -$1.5M |
| Free cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M | — |
| Cash & equivalents | $29.2M | $26.1M | — | $455,000 | $16.6M | — |
| Inventory | — | — | — | $2.2M | $1.8M | — |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M | $204,000 |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M | $2.9M |
| Shareholders' equity | $30.2M | $7.4M | -$3.8M | -$466,000 | $16.5M | -$2.7M |
Growth · year-over-year · Revenue CAGR -29%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | — | -29.0% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.